For research use only. Not for therapeutic Use.
TKB245(CAT: I040610) is a next-generation investigational HIV-1 capsid inhibitor with potent antiviral activity against a broad range of HIV-1 subtypes, including strains resistant to current therapies. It disrupts multiple stages of the viral lifecycle by targeting the capsid protein, impairing uncoating, reverse transcription, and nuclear import. TKB245 demonstrates favorable pharmacokinetics and a high barrier to resistance, making it a promising candidate for long-acting antiretroviral therapy (ART). This compound is ideal for researchers exploring novel mechanisms in HIV replication and treatment resistance.
| CAS Number | 2892688-16-1 |
| Synonyms | (1R,2S,5S)-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-N-[(2S)-1-(4-fluoro-1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| Molecular Formula | C30H35F4N5O5S |
| Purity | ≥95% |
| IUPAC Name | (1R,2S,5S)-3-[(2S)-3,3-dimethyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]-N-[(2S)-1-(4-fluoro-1,3-benzothiazol-2-yl)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide |
| InChI | InChI=1S/C30H35F4N5O5S/c1-28(2,3)22(38-27(44)30(32,33)34)26(43)39-12-14-18(29(14,4)5)20(39)24(42)36-16(11-13-9-10-35-23(13)41)21(40)25-37-19-15(31)7-6-8-17(19)45-25/h6-8,13-14,16,18,20,22H,9-12H2,1-5H3,(H,35,41)(H,36,42)(H,38,44)/t13-,14-,16-,18-,20-,22+/m0/s1 |
| InChIKey | UGXSZZAITMURED-MCUUEWDYSA-N |
| SMILES | CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C(=O)C4=NC5=C(C=CC=C5S4)F)C |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
